RARE Ultragenyx

$33.59

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Ultragenyx

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.

Website: https://www.ultragenyx.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1515673
Address
60 LEVERONI COURT, NOVATO, CA, US
Valuation
Market Cap
$3.35B
P/E Ratio
nan
PEG Ratio
-0.24
Price to Book
13.13
Performance
EPS
$-6.29
Dividend Yield
—
Profit Margin
-101.60%
ROE
-211.70%
Technicals
50D MA
$39.14
200D MA
$46.66
52W High
$60.37
52W Low
$29.59
Fundamentals
Shares Outstanding
94M
Target Price
$91.80
Beta
0.61

RARE EPS Estimates vs Actual

● Estimated
● Actual

RARE News & Sentiment

Nov 21, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 18,180 restricted stock units of the ...
Nov 05, 2025 • Zacks Commentary NEUTRAL
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
Nov 04, 2025 • Benzinga SOMEWHAT-BULLISH
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® ( burosumab ) for $400 Million to OMERS Life Sciences - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price Proceeds to fund four expected launches, setting the company up for the ...
Oct 28, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ...
Oct 28, 2025 • Benzinga SOMEWHAT-BULLISH
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ...
Oct 24, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., Oct. 24, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 20,317 restricted stock units of the ...
Sentiment Snapshot

Average Sentiment Score:

0.132
50 articles with scored sentiment

Overall Sentiment:

Neutral

RARE Reported Earnings

Aug 05, 2025
Jun 30, 2025 (Post market)
0.15 Surprise
  • Reported EPS: $-1.17
  • Estimate: $-1.32
  • Whisper: —
  • Surprise %: 11.4%
May 06, 2025
Mar 31, 2025 (Post market)
0.07 Surprise
  • Reported EPS: $-1.57
  • Estimate: $-1.64
  • Whisper: —
  • Surprise %: 4.3%
Feb 13, 2025
Dec 31, 2024 (Post market)
-0.12 Surprise
  • Reported EPS: $-1.39
  • Estimate: $-1.27
  • Whisper: —
  • Surprise %: -9.4%
Nov 05, 2024
Sep 30, 2024 (Post market)
0.07 Surprise
  • Reported EPS: $-1.40
  • Estimate: $-1.47
  • Whisper: —
  • Surprise %: 4.8%
Aug 01, 2024
Jun 30, 2024 (Post market)
0.17 Surprise
  • Reported EPS: $-1.52
  • Estimate: $-1.69
  • Whisper: —
  • Surprise %: 10.1%
May 02, 2024
Mar 31, 2024 (Post market)
-0.3 Surprise
  • Reported EPS: $-2.03
  • Estimate: $-1.73
  • Whisper: —
  • Surprise %: -17.3%
Feb 15, 2024
Dec 31, 2023 (Post market)
0.1 Surprise
  • Reported EPS: $-1.52
  • Estimate: $-1.62
  • Whisper: —
  • Surprise %: 6.2%
Nov 02, 2023
Sep 30, 2023 (Post market)
-0.15 Surprise
  • Reported EPS: $-2.23
  • Estimate: $-2.08
  • Whisper: —
  • Surprise %: -7.2%
Aug 03, 2023
Jun 30, 2023 (Post market)
-0.18 Surprise
  • Reported EPS: $-2.25
  • Estimate: $-2.07
  • Whisper: —
  • Surprise %: -8.7%

Financials